Table 1.
Baseline characteristics of patients with and without late recurrence following catheter ablation.
| Without late recurrence (n = 130) | With late recurrence (n = 47) | P value | |
|---|---|---|---|
| Age (years) | 59 ± 10 | 60 ± 10 | 0.626 |
| Age > 65 years | 35 (27) | 16 (34) | 0.356 |
| Female sex | 16 (12) | 11 (23) | 0.070 |
| Height (cm) | 167 ± 7 | 166 ± 8 | 0.604 |
| Body weight (kg) | 72 ± 11 | 71 ± 12 | 0.552 |
| BMI (kg/m2) | 26 ± 3 | 26 ± 4 | 0.686 |
| Persistent atrial fibrillation | 58 (45) | 30 (64) | 0.024 |
| AF duration (month) | 23 ± 25 | 36 ± 41 | 0.054 |
| Heart failure | 4 (3) | 7 (15) | 0.009 |
| Hypertension | 49 (38) | 13 (28) | 0.217 |
| Diabetes mellitus | 21 (16) | 9 (19) | 0.639 |
| Prior stroke or TIA or SE | 11 (8.5) | 9 (19) | 0.047 |
| Vascular disease | 8 (6) | 4 (9) | 0.582 |
| TTE findings | |||
| LA diameter (mm) | 41 ± 6 | 43 ± 7 | 0.090 |
| LA diameter ≥ 43 mm | 49 (38) | 23 (49) | 0.179 |
| LVEF (%) | 69 ± 9 | 68 ± 13 | 0.515 |
| LVEF < 50% | 3 (2.3) | 4 (8.5) | 0.082 |
| LV mass index (g/m2) | 87 ± 19 | 90 ± 28 | 0.452 |
| Laboratory findings | |||
| eGFR (ml/min/1.73 m2) | 95 ± 21 | 88 ± 22 | 0.055 |
| eGFR < 60 ml/min/1.73 m2 | 5 (4) | 3 (6) | 0.359 |
| CHA2DS2-VASc score, median (IQR) | 1 (0–2) | 1 (0–2) | 0.299 |
| APPLE score, median (IQR) | 1 (0–2) | 1 (1–2) | 0.026 |
Results are presented as n (%) or means with standard deviation. AF, atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; LA, left atrium; LV, left ventricle, LVEF, left ventricular ejection fraction; SE, systemic embolism; TIA, transient ischemic attack; TTE, transthoracic echocardiography.